Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-158-7 | CAS number: 13674-84-5
Toxicological Summary
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 5.82 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 12.5
- Modified dose descriptor starting point:
- LOAEC
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 5.82 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 12.5
- Modified dose descriptor starting point:
- LOAEC
Local effects
Long term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- irritation (respiratory tract)
Acute/short term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- irritation (respiratory tract)
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.08 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- LOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.08 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- LOAEL
Local effects
Long term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- skin irritation/corrosion
Acute/short term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- skin irritation/corrosion
Workers - Hazard for the eyes
Additional information - workers
For the inhalation, dermal and oral exposure routes, ‘short-term’ exposures will be assessed using the long-term DNELs.
Long-term inhalation route-systemic (worker) using extrapolations factors:
Calculation according to EU Draft RAR dated May 2008:
LOAEL (rat) oral: 52 mg/kg bw/day
"Normally a further factor of 3 would be used to take into account the use of a LOAEL rather than a NOAEL. However this is not considered necessary here, as the adverse effect in the repeated dose toxicity study (mainly liver weight changes are not considered particularly toxicologically significant and the LOAEL is probably quite close to the NOAEL. "
NOEL (rat) oral: 52 mg/kg bw/day
ABS oral rat=80 %
ABS inhalativ human= 100 %
80/100 =0.8
52*0.8= 41.6 mg/kg bw/d
Corrected NOAEL (rat) oral: 41.6 mg/kg bw
For interspecies differences rat vs. human 4
41.6 mg/kg: 4 = 10.4 mg/kg bw/d
Body weight worker = 70 kg bw/person
10.4 mg/kg * 70 kg bw/person= 728 mg/person/d
Respiratory volume worker = 10 m³/person (8h exposure; light activity for worker)
728 mg/person/d: 10 m³/person = 72.8 mg/m³/8h
NOEC worker (8h) = 72.8 mg/m³
For remaining interspecies 2.5
For intraspecies differences in worker 5
"A factor to allow for semi (sub) -chronic to chronic extrapolation (usually a factor of 2) was not used here. It is not considered necessary, as relatively similar effects on the liver, at doses of a comparable order of magnitude were observed in both the 28-day and the 90-day studies and so it felt that exposure duration is not significant. "
For reliability of dose response 1
For quality of whole database 1
Overall factor 12.5
Worker DNEL long-term for inhalation route-systemic = 5.82 mg/m³/8h
Long-term dermal route-systemic (worker) using extrapolation factors:
Calculation according to EU Draft RAR dated May 2008:
LOAEL (rat) oral: 52 mg/kg bw/day
"Normally a further factor of 3 would be used to take into account the use of a LOAEL rather than a NOAEL. However this is not considered necessary here, as the adverse effect in the repeated dose toxicity study (mainly liver weight changes are not considered particularly toxicologically significant and the LOAEL is probably quite close to the NOAEL. "
NOEL (rat) oral: 52mg/kg bw/day
ABS (rat) oral= 80%
ABS dermal= 40 % (foam) – this is a worst case scenario because in the EU Draft RAR dated May 2008 a total absorption value of 23% is taken forward to risk characterisation for scenarios where there is exposure to "neat" TCPP and 40% dermal absorption is taken forward for those scenarios where there is exposure due to handling of foam containing TCPP".
80:40=2
Corrected NOAEL= 104 mg/kg bw/day
For interspecies differences rat vs. human 4
For remaining interspecies differences: 2.5
For intraspecies differences in worker 5
"A factor to allow for semi (sub) -chronic to chronic extrapolation (usually a factor of 2) was not used here. It is not considered necessary, as relatively similar effects on the liver, at doses of a comparable order of magnitude were observed in both the 28-day and the 90-day studies and so it felt that exposure duration is not significant. "
For reliability of dose response 1
For quality of whole database 1
Overall factor: 50
Worker-DNEL long-term for dermal route systemic = 2.08 mg/kg bw/d
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.46 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 25
- Modified dose descriptor starting point:
- LOAEC
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.46 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 25
- Modified dose descriptor starting point:
- LOAEC
Local effects
Long term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
Acute/short term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- irritation (respiratory tract)
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.04 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- LOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.04 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- LOAEL
Local effects
Long term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- acute toxicity
Acute/short term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- skin irritation/corrosion
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.52 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- LOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.52 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- LOAEL
General Population - Hazard for the eyes
Additional information - General Population
For the inhalation, dermal and oral exposure routes, ‘short-term’ exposures will be assessed using the long-term DNELs.
Long-term inhalation route-systemic (general population) using extrapolations factors:Calculation according to EU Draft RAR dated May 2008:
LOAEL (rat) oral: 52 mg/kg bw/day
"Normally a further factor of 3 would be used to take into account the use of a LOAEL rather than a NOAEL. However this is not considered necessary here, as the adverse effect in the repeated dose toxicity study (mainly liver weight changes are not considered particularly toxicologically significant and the LOAEL is probably quite close to the NOAEL. "
NOEL (rat) oral: 52 mg/kg bw/day
ABS oral rat=80 %
ABS inhalativ human= 100 %
80/100 =0.8
52*0.8= 41.6 mg/kg bw/d
Corrected NOAEL (rat) oral: 41.6 mg/kg bw
For interspecies differences rat vs. human 4
41.6 mg/kg: 4 = 10.4 mg/kg
Body weight general public = 70 kg bw/person
10.4 mg/kg * 70 kg bw/person= 728 mg/person/d
Respiratory volume general population: 20 m³/person (24h exposure; general population)
728 mg/person/d: 20 m³/person = 36.4 mg/m³/24 h
NOEC general population (24h) = 36.4 mg/m³/24h
For remaining interspecies differences: 2.5
For intraspecies differences in general population: 10
"A factor to allow for semi (sub) -chronic to chronic extrapolation (usually a factor of 2) was not used here. It is not considered necessary, as relatively similar effects on the liver, at doses of a comparable order of magnitude were observed in both the 28-day and the 90-day studies and so it felt that exposure duration is not significant. "
For reliability of dose response 1
For quality of whole database 1
Overall factor: 25
General population DNEL long-term for inhalation route systemic = 1.46 mg/m³/24 h
Long-term oral route-systemic (general population) using extrapolation factors:
Calculation according to EU Draft RAR dated May 2008:
LOAEL (rat) oral: 52 mg/kg bw/day
"Normally a further factor of 3 would be used to take into account the use of a LOAEL rather than a NOAEL. However this is not considered necessary here, as the adverse effect in the repeated dose toxicity study (mainly liver weight changes are not considered particularly toxicologically significant and the LOAEL is probably quite close to the NOAEL. "
NOEL (rat) oral: 52 mg/kg bw/day
For interspecies differences rat vs. human 4
For remaining interspecies differences: 2.5
For intraspecies differences in general population 10
"A factor to allow for semi (sub) -chronic to chronic extrapolation (usually a factor of 2) was not used here. It is not considered necessary, as relatively similar effects on the liver, at doses of a comparable order of magnitude were observed in both the 28-day and the 90-day studies and so it felt that exposure duration is not significant. "
For reliability of dose response 1
For quality of whole database 1
Overall factor: 100
General population-DNEL long-term for dermal (oral) route systemic = 0.52 mg/kg bw/d
Long-term dermal route-systemic (general population) using extrapolation factors:
Calculation according to EU Draft RAR dated May 2008:
LOAEL (rat) oral: 52 mg/kg bw/day
"Normally a further factor of 3 would be used to take into account the use of a LOAEL rather than a NOAEL. However this is not considered necessary here, as the adverse effect in the repeated dose toxicity study (mainly liver weight changes are not considered particularly toxicologically significant and the LOAEL is probably quite close to the NOAEL. "
NOEL (rat) oral: 52mg/kg bw/day
ABS (rat) oral= 80%
ABS dermal= 40% - this is a worst case scenario because in the EU Draft RAR dated May 2008 a total absorption value of 23% is taken forward to risk characterisation for scenarios where there is exposure to "neat" TCPP and 40% dermal absorption is taken forward for those scenarios where there is exposure due to handling of foam containing TCPP".
80:40=2
Corrected NOAEL= 104 mg/kg bw/day
For interspecies differences rat vs. human 4
For remaining interspecies differences: 2.5
For intraspecies differences in general population 10
"A factor to allow for semi (sub) -chronic to chronic extrapolation (usually a factor of 2) was not used here. It is not considered necessary, as relatively similar effects on the liver, at doses of a comparable order of magnitude were observed in both the 28-day and the 90-day studies and so it felt that exposure duration is not significant. "
For reliability of dose response 1
For quality of whole database 1
Overall factor: 100
General population-DNEL long-term for dermal route systemic = 1.04 mg/kg bw/d
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
